Update from Lexeo Therapeutics
In a press release on Monday, March 30, 2026, Lexeo Therapeutics reported their fourth quarter and full year 2025 financial results as well as operational highlights on their FA program including:
- The initiation of the SUNRISE-FA 2 pivotal trial is anticipated in 1H2026. The protocol for this trial is currently under review by the FDA.
- Lexeo expects to receive final feedback from the FDA in the second quarter of 2026 and plans to provide a more detailed update at that time.
- Lexeo is proceeding with readiness activities to support the Biologic License Application (BLA) submission for LX2006.
Learn more about the LX2006 program on our pipeline page.
